No Evidence for Recent Abacavir/Lamivudine Use in Promoting Inflammation, Endothelial Dysfunction, Hypercoagulability, or Insulin Resistance in Virologically.

Slides:



Advertisements
Similar presentations
1 Radio Maria World. 2 Postazioni Transmitter locations.
Advertisements

Números.
1 A B C
Trend for Precision Soil Testing % Zone or Grid Samples Tested compared to Total Samples.
Trend for Precision Soil Testing % Zone or Grid Samples Tested compared to Total Samples.
AGVISE Laboratories %Zone or Grid Samples – Northwood laboratory
Trend for Precision Soil Testing % Zone or Grid Samples Tested compared to Total Samples.
Cardiovascular Side Effects of HIV Treatment
Fill in missing numbers or operations
/ /17 32/ / /
Reflection nurulquran.com.
1
EuroCondens SGB E.
Worksheets.
STATISTICS INTERVAL ESTIMATION Professor Ke-Sheng Cheng Department of Bioenvironmental Systems Engineering National Taiwan University.
Addition and Subtraction Equations
Multiplication X 1 1 x 1 = 1 2 x 1 = 2 3 x 1 = 3 4 x 1 = 4 5 x 1 = 5 6 x 1 = 6 7 x 1 = 7 8 x 1 = 8 9 x 1 = 9 10 x 1 = x 1 = x 1 = 12 X 2 1.
Division ÷ 1 1 ÷ 1 = 1 2 ÷ 1 = 2 3 ÷ 1 = 3 4 ÷ 1 = 4 5 ÷ 1 = 5 6 ÷ 1 = 6 7 ÷ 1 = 7 8 ÷ 1 = 8 9 ÷ 1 = 9 10 ÷ 1 = ÷ 1 = ÷ 1 = 12 ÷ 2 2 ÷ 2 =
OPTN Modifications to Heart Allocation Policy Implemented July 12, 2006 Changed the allocation order for medically urgent (Status 1A and 1B) patients Policy.
Cardiovascular Risk and dyslipidemia
David Burdett May 11, 2004 Package Binding for WS CDL.
1 When you see… Find the zeros You think…. 2 To find the zeros...
Create an Application Title 1Y - Youth Chapter 5.
Add Governors Discretionary (1G) Grants Chapter 6.
CALENDAR.
CHAPTER 18 The Ankle and Lower Leg
Summative Math Test Algebra (28%) Geometry (29%)
ASCII stands for American Standard Code for Information Interchange
The 5S numbers game..
A Fractional Order (Proportional and Derivative) Motion Controller Design for A Class of Second-order Systems Center for Self-Organizing Intelligent.
Break Time Remaining 10:00.
The basics for simulations
PP Test Review Sections 6-1 to 6-6
MM4A6c: Apply the law of sines and the law of cosines.
1 2 Teeth and Function 3 Tooth structure 4 Dental Problems.
Regression with Panel Data
TCCI Barometer March “Establishing a reliable tool for monitoring the financial, business and social activity in the Prefecture of Thessaloniki”
TCCI Barometer March “Establishing a reliable tool for monitoring the financial, business and social activity in the Prefecture of Thessaloniki”
Copyright © 2012, Elsevier Inc. All rights Reserved. 1 Chapter 7 Modeling Structure with Blocks.
Progressive Aerobic Cardiovascular Endurance Run
Biology 2 Plant Kingdom Identification Test Review.
Visual Highway Data Select a highway below... NORTH SOUTH Salisbury Southern Maryland Eastern Shore.
Adding Up In Chunks.
MaK_Full ahead loaded 1 Alarm Page Directory (F11)
Artificial Intelligence
When you see… Find the zeros You think….
2011 WINNISQUAM COMMUNITY SURVEY YOUTH RISK BEHAVIOR GRADES 9-12 STUDENTS=1021.
Before Between After.
2011 FRANKLIN COMMUNITY SURVEY YOUTH RISK BEHAVIOR GRADES 9-12 STUDENTS=332.
Subtraction: Adding UP
: 3 00.
5 minutes.
Numeracy Resources for KS2
1 Non Deterministic Automata. 2 Alphabet = Nondeterministic Finite Accepter (NFA)
1 hi at no doifpi me be go we of at be do go hi if me no of pi we Inorder Traversal Inorder traversal. n Visit the left subtree. n Visit the node. n Visit.
Northern Lakes Community Mental Health CS Research & Consulting Cathlyn Sommerfield, Ph.D. October 2013.
Static Equilibrium; Elasticity and Fracture
ANALYTICAL GEOMETRY ONE MARK QUESTIONS PREPARED BY:
Converting a Fraction to %
Resistência dos Materiais, 5ª ed.
Clock will move after 1 minute
Copyright © 2013 Pearson Education, Inc. All rights reserved Chapter 11 Simple Linear Regression.
Physics for Scientists & Engineers, 3rd Edition
Doc.: IEEE /0333r2 Submission July 2014 TGaj Editor Report for CC12 Jiamin Chen, HuaweiSlide 1 Date: Author:
Select a time to count down from the clock above
Copyright Tim Morris/St Stephen's School
1 Dr. Scott Schaefer Least Squares Curves, Rational Representations, Splines and Continuity.
1 Non Deterministic Automata. 2 Alphabet = Nondeterministic Finite Accepter (NFA)
Schutzvermerk nach DIN 34 beachten 05/04/15 Seite 1 Training EPAM and CANopen Basic Solution: Password * * Level 1 Level 2 * Level 3 Password2 IP-Adr.
Presentation transcript:

No Evidence for Recent Abacavir/Lamivudine Use in Promoting Inflammation, Endothelial Dysfunction, Hypercoagulability, or Insulin Resistance in Virologically Suppressed HIV-infected patients: A Sub-study of the BICOMBO Randomized Clinical Trial E. Martínez, M. Larrousse, I. Pérez, M. Loncá, D. Podzamczer, F. Gutiérrez, R. Deulofeu, R. Casamitjana, J.C. Reverter, J. Mallolas, J. Pich, J.M. Gatell, for the BICOMBO Study Group SPAIN

ABACAVIR AND CV DISEASE Abacavir use identified as a marker of cardiovascular disease in several cohort studies (1-3), although it is currently unclear whether its role is causative or not. Potential pathogenetic mechanisms are also unclear. Abacavir has not been asociated with insulin resistance (4) or lipoatrophy (4, 5) and its lipid impact is lower than that of stavudine (5) or protease inhibitors (6), although higher than that of tenofovir (7). Several potential mechanisms affecting biological mechanisms associated with cardiovascular dysfunction have been suggested (6-8) but studies to date may have been subjected to bias. 1. D:A:D Study Group. Lancet 2008; 371: 1417-1426 2. The SMART/INSIGHT and the D:A:D Study Groups. AIDS 2008; 22: F17-F24 3. Obel N, et al. HIV Medicine 2009 (Epub ahead of print) 4. Shlay JC, et al. JAIDS 2005; 38: 147-155 5. Podzamczer D, et al. J Acquir Immune Defic Syndr. 2007; 44: 139-147 6. Martinez E, et al. N Engl J Med 2003; 349: 1036-1046 7. Smith KY, et al. AIDS 2009; 23: 1547-1556 6. Hsue PY, et al. AIDS. 2009; 23: 2021-2027 7. Satchell C, et al. 16th CROI, 2009. Montreal, Canada. Abstract 151LB 8. Kristoffersen US, et al. HIV Medicine 2009 (Epub ahead of print)

D:A:D STUDY: ABC, TDF, and MYOCARDIAL INFARCTION Cumm. use Recent use 1.9 1.5 1.5 RR yes/no 95%CI 1.2 1.2 RR per year 95%CI ** 1 1 0.8 0.8 0.6 0.6 ZDV ddI ddC d4T 3TC ABC TDF #PYFU: 138,109 74,407 29,676 95,320 152,009 53,300 39,157 #MI: 523 331 148 405 554 221 139 J Lundgren & DAD Study Group et al CROI 2009 LB abstr 44

MECHANISMS FOR MYOCARDIAL INFARCTION TDF 3 Initiation Progression Complication Inflammation Endothelial dysfunction Insulin resistance Hypercoagulability ABC 1-3 1. D:A:D Study Group. Lancet 2008. 2. The SMART/INSIGHT and the D:A:D Study Groups. AIDS 2008. 3. D:A:D Study Group. CROI 2009.

POTENTIAL SOURCES OF CONFOUNDING AND BIAS Drug prescription not random Pre-existing CV disease or DM Uncontrolled HIV infection or AIDS

BICOMBO STUDY DESIGN Primary Analysis, Week 48 Patients randomized (n=335) PI=34 NNRTI=301 Stable 3TC-based ART for > 6 months HIV-RNA < 200c/mL No HLA screening ABC/3TC (n=167) TDF/FTC (n=168) Excluded (n=0) Excluded (n=2) ABC/3TC (n=167) TDF/FTC (n=166) Primary Analysis, Week 48 Discontinue ABC/3TC (n=30, 18%) Discontinue TDF/FTC (n=22, 13%) Continue on ABC/3TC (n=137, 82%) * Continue on TDF/FTC (n=144, 87%) * 1 patient with virological failure and 1 with a new AIDS event Martinez E et al. J Acquir Immune Defic Syndr 2009.

Endothelial dysfunction METHODS Patients Baseline and 48w serum samples available No history of symptomatic CV disease or DM No virological failure or AIDS events during follow-up Laboratory markers Statistical analyses Wilcoxon rank Sum test for comparisons Punctual estimation and 95% confidence interval of difference in medians (methodology of Hodges-Lehman, using the distribution-free of Moses). Spearman test for correlations Initiation Progression Complication Inflammation Endothelial dysfunction Insulin resistance Hypercoagulability hsCRP, MCP-1 OPG, IL-6 TNF-alpha IL-10 D-dimer ICAM-1, VCAM-1 Selectin E, Selectin P Adiponectin, Insulin

POPULATION CHARACTERISTICS BICOMBO Sub-study BICOMBO Study ABC/3TC (n=46) TDF/FTC (n=34) Patients in the Sub-study (n=80) Patients not in the Sub-study (n=253) Age (years) 44 (39-52) 42 (37-49) 43 (38-48) Male gender (n, %) 38 (82.6) 26 (76.5) 64 (80.0) 195 (77.1) Years of ART 4.5 (2.2-6.4) 3.7 (2.1-6.3) 3.9 (2.1-6.2) 3.9 (2.1-6.4) PI at baseline (n, %) 4 (8.7) 2 (5.9) 6 (7.5) 24 (9.5) Active smoker (n, %) 12 (26.1) 8 (23.5) 20 (25.0) 68 (26.9) Systolic BP (mmHg) 125 (111-142) 122 (106-140) 124 (109-141) 125 (107-142) Total chol (mg/dL) 205 (166-225) 205 (177-227) 205 (175-227) 205 (176-229) HDL chol (mg/dL) 49 (44-64) 50 (41-61) 49 (42-63) 49 (42-62) Framingham score 5.5 (1.8-9.7) 3.8 (2.9-10.3) 4.4 (1.9-10.3) 4.3 (1.9-10.1) P>0.05 for all comparisons between groups (ABC/3TC vs TDF/FTC) in the Sub-study. P>0.05 for all comparisons between patients in the Sub-study vs patients from the BICOMBO study not in the Sub-study.

BIOMARKERS AT BASELINE and 48 WEEKS Median laboratory marker (units) ABC/3TC (n=46) TDF/FTC (n=34) P value for comparisons between baseline values P value for comparisons between 48 week values Baseline 48 weeks hsCRP (mg/L) 0.13 0.14 0.10 0.91 MCP-1 (pg/mL) 76 71 83 87 0.27 0.17 OPG (pmol/L) 4.1 4.2 4.3 0.89 0.56 IL-6 (pg/mL) 0.70 1 IL-10 (pg/mL) 3.9 0.47 0.42 TNF- (pg/mL) 1.6 0.54 ICAM-1 (ng/mL) 198 188 194 213 0.58 0.45 VCAM-1 (ng/mL) 394 372 410 413 0.43 0.22 Selectin E (ng/mL ) 119 115 121 126 0.92 0.44 Selectin P (ng/mL) 114 104 122 0.28 0.69 Insulin (mU/L) 8.9 8.3 9.7 10.3 0.18 Adiponectin (g/mL) 8.0 7.8 9.6 0.40 0.33 D-dimer (mg/L) 0.20 0.21 0.06 0.24

CORRELATIONS BETWEEN BASELINE PARAMETERS Spearman Correlation Coefficient P-value Selectin E – Selectin P 0.63 <0.0001 ICAM-1 – VCAM-1 0.51 OPG – Adiponectin 0.29 0.015 Insulin - Adiponectin -0.25 0.030 Spearman Correlation Coefficient P-value Framingham – OPG 0.31 0.008 Framingham – Selectin E 0.29 0.016 Framingham – Selectin P 0.26 0.032

CHANGE IN BIOMARKERS FROM BASELINE TO 48 WEEKS Median Laboratory marker (units) ABC/3TC (n=46) TDF/FTC (n=34) P value for comparisons between absolute changes P value for comparisons between percent changes Median difference of percent change ABC/3TC minus TDF/FTC [lower confidence interval, upper confidence interval] Percent change hsCRP (mg/L) -3.9 0.0 0.76 0.26 26.4 [-15.4, 100] MCP-1 (pg/mL) 5.9 4 0.35 0.52 9.5 [-14.2, 30.4] OPG (pmol/L) 5.1 -2.8 0.51 0.59 2.9 [-8.7, 14.4] IL-6 (pg/mL) 0.49 0 [0, 0] IL-10 (pg/mL) 0.11 0.12 0 [0, 2] TNF- (pg/mL) 0.28 0.31 ICAM-1 (ng/mL) 6.6 5.2 0.65 0.84 -15.9 [-17.1,16.2] VCAM-1 (ng/mL) 0.02 -0.01 0.88 0.73 -0.02 [-0.16, 0.11] Selectin E (ng/mL ) -0.4 7.8 0.19 0.13 -8.5 [-17.3, 2.1] Selectin P (ng/mL) 4.6 12.6 0.37 0.33 -7.9 [-21.3, 6.3] Insulin (mU/L) -2.5 8.8 0.67 0.69 7.4 [-27.9, 38.4] Adiponectin (g/mL) -2.2 15.4 0.10 -15.9 [-36.3, 4.0] D-dimer (mg/L) 0.00 0 [-18.0, 5.6]

CHANGE IN HIGH-SENSITIVITY CRP Because hsCRP is the marker with more widespread clinical use, we performed additional analyses. Absolute hsCRP increase at 48 weeks: 18(39%) and 11 (32%) patients in the ABC/3TC and TDF/FTC groups respectively (P=0.62). hsCRP higher than 0.5 mg/dL at 48 weeks: 4(9%) and 1 (3%) patients in the ABC/3TC and TDF/FTC groups respectively (P=0.39). hsCRP increase at 48 weeks 25% higher than that at the baseline: 16(35%) and 9 (26%) patients in the ABC/3TC and TDF/FTC groups respectively (P=0.61). 12

CONCLUSIONS In otherwise healthy, virologically suppressed HIV-infected patients from the BICOMBO study, the initiation of ABC/3TC did not lead to significant changes after 48 weeks in markers of inflammation, endothelial dysfuntion, insulin resistance, or hypercoagulability as compared with the initiation of TDF/FTC. These results argue against any of these mechanisms as involved in the higher risk of MI associated with recent ABC use in some cohort studies. 13

ACKNOWLEDGEMENTS Supported in part by research grants from Gilead Sciences and GlaxoSmithKline Participating centers and investigators (in alphabetical order): Hospital de Bellvitge, L’Hospitalet (Patricia Barragán, Elena Ferrer, Daniel Iñiguez, Gabriela Leibenger, Daniel Podzamczer) Hospital Clínic, Barcelona (Mireia Arnedo, José L Blanco, Marta Calvo, José M Gatell, Montserrat Laguno, María Larrouse, Agathe León, Montserrat Loncá, Josep Mallolas, Esteban Martínez, María Martínez, Ana Milinkovic, José M. Miró, Tomás Pumarola) Hospital Clínico de San Carlos, Madrid (Mónica Fuster, Victor Roca†) Hospital General Universitario de Elche, Elche (Enrique Bernal, Félix Gutiérrez, Mar Masiá, Sergio Padilla). Hospital Germans Trías i Pujol, IrsiCaixa Foundation, Badalona (Isabel Bravo, Bonaventura Clotet, Patricia Echeverría). Hospital Gregorio Marañón, Madrid (Juan Berenguer, Jaime Cosín, Isabel Gutiérrez, Margarita Ramírez, Matilde Sánchez) Hospital Universitari de Tarragona Joan XXIII, Universitat Rovira i Virgili, Tarragona (Joaquim Peraire, Francesc Vidal) Hospital del Mar, Barcelona (Hernando Knobel, Alicia González) Hospital de Mataró, Mataró (Luis Force, Pilar Barrufet) Hospital de Mútua de Terrassa, Terrassa (Mireia Cairó, David Dalmau, Carol García) Hospital Parc Taulí, Sabadell (Esperanza Antón, Eva Penelo, Ferran Segura) Hospital Universitario La Paz, Madrid (José R Arribas, Juan Miguel Castro, María Montes) Hospital Universitario de La Princesa, Madrid (Raquel Carrillo, Ignacio de los Santos) Hospital Príncipe de Asturias, Alcalá de Henares (Jose A Arranz, Esperanza Casas, Julio de Miguel, José Sanz) Hospital Sant Jaume, Calella (Josep M Llibre, Silvia Valero) Hospital Son Llàtzer, Palma de Mallorca (Antoni Payeras) Hospital de Sierrallana, Torrelavega (Francisco Galo) Hospital Vall d’Hebron, Barcelona (Esteban Ribera, Adrià Curran) Special thanks to study patients 14